Diaxxo AG

We are seeing a tectonic shift in healthcare infrastructure as we know it, powered by the smartphone revolution, and dianax is at the cutting-edge of mobile diagnostic transformation. The ongoing development of dianax lab-on-a-chip has been made possible thanks to investment from multiple sources. We are indebted to those in the European Commission who recognized early on the extraordinary potential of our technology in changing the face of diagnostic testing and awarded a significant grant through their Horizon 2020 Program. We are always happy to hear from interested parties. We have partnered with experts in rapid diagnostics – BioSpeedia (a spin-off of Institut Pasteur) – to bring to market a reliable test for rapid detection and differentiation of antibodies to novel coronavirus SARS-CoV-2. The COVID19SEROSpeed-IgM-IgG Rapid Test is now distributed by dianax in Italy, Belgium, Luxembourg, the Netherlands, Greece, Spain and Portugal. By bringing laboratory-grade disease screening, diagnosis and monitoring to the patient, dianax is taking diagnostics straight to the POINT OF NEED. While HbA1c-glycated hemoglobin blood testing for diabetes is our primary focus, the dianax lab-on-a-chip can test any protein extracted from bodily fluids (blood, urine, saliva), and so has the potential to transform diagnostic testing across a number of therapy areas.

We are a medical diagnostics company with portable PCR testing technology that may be implemented in both clinical and mobile laboratory settings. Watch our video to learn more about our mission and story. Click Diagnostics explores a number of markets and identifies sexual health as the direction to pursue. Small enough to fit in the palm of your hand, the PCR test delivers rapid and accurate results. NIH sponsors the FDA clinical study for the sexual health product. Our rapid PCR tests provide accurate and reliable results for healthcare providers all across the United States. In a world where speed and accuracy in disease testing has become increasingly important, the efficient protection of public health depends on the delivery of fast and reliable infectious disease testing to affected communities as quickly as possible. The Visby Medical portable, instrument-free PCR test delivers results in minutes, not days, making our PCR test kits a revolution in the molecular diagnostics industry.

Creating the next generation of lateral flow devices. SwiftDx’s portfolio of patented technologies enable ultra-boosted sensitivity lateral flow diagnostics for diseases which are undetectable with current lateral flow test technology. SwiftDx has successfully completed the initial technology development phase and is ready to commercialise its DNA detection and eAMP technologies. The company’s first product (the SwiftDx Mycoplasma Detection kit) has been launched and a further products are in development. Our goal is to better inform patients and healthcare practitioners with a new generation of lateral flow tests.

We provide, with a simple blood draw, a multiparametric, qualitative and quantitative analysis of tumour-derived circulating DNA with unprecedented sensitivity level. DiaDx has built a strong expertise in all pre-analytical conditions revolving around an optimal circulating DNA analysis and follows its own stringent Standard Operating Procedures under Good Clinical Laboratory Practice (GCLP) guidelines. As such, IntPlex® provides a real-time analysis of the molecular evolution of the tumour providing information on the mutant clones dynamics during all phases of patient management care. IntPlex® is a sophisticated quantitative PCR-based method much more cost-effective (2 to 3-times) than any other competitor system.

With CYCLE® Dx we provide a unique solution for true Point-of-Care diagnostics. CYCLE® Dx provides the complete diagnostic workflow in a miniaturised environment and transfers Point-of-Care diagnostics to the next level:. Furthermore, we offer our customers state of the art oligonucleotides, phosphoramidites and nanoparticles.

Our mission is to bring dramatic, life-changing improvements to healthcare and beyond with fast, simple and scientifically sound products. DNAe Group Holdings LtdScale Space58 Wood Lane London W12 7RZ United Kingdom. At DNAe we are leading the way in rapid, near-patient sequencing testing that will revolutionize patient care for a range of unmet clinical needs. DNAe is developing the LiDia-SEQ™ Platform, a direct-from-specimen diagnostic system that performs DNA sequencing on a microchip, to provide rapid, actionable information to clinicians. We are creating radically different products that change the game for early diagnosis and monitoring of potentially fatal diseases. Regius Professor Chris Toumazou FRS, FREng, FMedSci founded the company in 2003, as a spin-out from Imperial College London, having invented a way of detecting protons released during DNA synthesis to enable DNA sequence detection using a standard silicon-chip based transistor. Regius Professor Chris Toumazou FRS, FREng, FMedSci founded the company in 2003, as a spin-out from Imperial College, London, having invented a way of detecting protons released during DNA synthesis to enable DNA sequence detection using a standard silicon-chip based transistor. The user-friendly system can operate in a variety of hospital environments at the point-of-need, with flexible levels of throughput to match a wide range of clinical demands.‍Our initial focus is on infectious disease diagnostics, where speed and microbial DNA sequence information can make the difference between life and death.